Gastroenterology
Volume 134, Issue 1 , Pages 95-101, January 2008

Pancreatic Cancer–Associated Diabetes Mellitus: Prevalence and Temporal Association With Diagnosis of Cancer

  • Suresh T. Chari

      Affiliations

    • Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota
    • Corresponding Author InformationAddress requests for reprints to: Suresh T. Chari, MD, Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester Minnesota 55905. fax: (507) 284-0538.
  • ,
  • Cynthia L. Leibson

      Affiliations

    • Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, Minnesota
  • ,
  • Kari G. Rabe

      Affiliations

    • Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, Minnesota
  • ,
  • Lawrence J. Timmons

      Affiliations

    • Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota
  • ,
  • Jeanine Ransom

      Affiliations

    • Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, Minnesota
  • ,
  • Mariza de Andrade

      Affiliations

    • Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, Minnesota
  • ,
  • Gloria M. Petersen

      Affiliations

    • Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, Minnesota

Received 24 July 2007; accepted 11 October 2007. published online 29 October 2007.

Background & Aims: The temporal association between diabetes mellitus and pancreatic cancer is poorly understood. We compared temporal patterns in diabetes prevalence in pancreatic cancer and controls. Methods: We reviewed the medical records of pancreatic cancer cases residing within 120 miles or less of Rochester, Minnesota, seen at the Mayo Clinic between January 15, 1981, and July 9, 2004, and approximately 2 matched controls/case residing locally. We abstracted all outpatient fasting blood glucose (FBG) levels for up to 60 months before index (ie, date of cancer diagnosis for cases) and grouped them into 12-month intervals; 736 cases and 1875 controls had 1 or more outpatient FBG levels in the medical record. Diabetes was defined as any FBG level of 126 mg/dL or greater or treatment for diabetes, and was defined as new onset when criteria for diabetes were first met 24 or fewer months before index, with at least 1 prior FBG level less than 126 mg/dL. Results: A higher proportion of pancreatic cancer cases compared with controls met the criteria for diabetes at any time in the 60 months before index (40.2% vs 19.2%, P < .0001). The proportions were similar in the −60 to −48 (P = .76) and −48 to −36 (P = .06) month time periods; however, a greater proportion of cases than controls met criteria for diabetes in the −36 to −24 (P = .04), −24 to −12 (P < .001), and −12 to 0 (P < .001) month time periods. Diabetes was more often new onset in cases vs controls (52.3% vs 23.6%, P < .0001). Conclusions: Diabetes has a high (40%) prevalence in pancreatic cancer and frequently is new onset. Identification of a specific biomarker for pancreatic cancer–induced diabetes may allow screening for pancreatic cancer in new-onset diabetes.

Abbreviations used in this paper: BMI, body mass index, DM, diabetes mellitus, FBG, fasting blood glucose, PaC, pancreatic cancer, PaCDM, new-onset diabetes mellitus associated with pancreatic cancer

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported by grants from the National Institutes of Health (R01 CA 100685 and P50 CA 10270 to S.T.C., R01 CA 100685 and P50 CA 10270 to G.M.P. and M.d.A.), the Lustgarten Foundation (to S.T.C.), and by grants from SmithKline Beecham Pharmaceuticals (to C.L.L.).

PII: S0016-5085(07)01920-8

doi:10.1053/j.gastro.2007.10.040

Refers to article:

  • Pancreatic Cancer: Cause and Result of Diabetes Mellitus

    Niels Teich
    Gastroenterology January 2008 (Vol. 134, Issue 1, Pages 344-345)

  • Continuing Medical Education Exam 1: January 2008

    Michael B. Wallace
    Gastroenterology January 2008 (Vol. 134, Issue 1, Pages 324-325)

Gastroenterology
Volume 134, Issue 1 , Pages 95-101, January 2008